Entering text into the input field will update the search result below

After two years of under-performance shares of Novartis (NYSE:NVS) could be poised for gains...

Nov. 20, 2012 7:46 PM ETNovartis AG (NVS) StockNVSBy: David Yelle, SA News Editor4 Comments
After two years of under-performance shares of Novartis (NYSE:NVS) could be poised for gains going into next year, according to Barron's. The report cites a promising pipeline of drugs, a 4% dividend and a below-market multiple, all of which should pay off handsomely over the near-term. Additionally, nearly 30% of the company's sales come from drugs that have come to market just since 2007, which Barron's attributes to the company's continued heavy investment into R&D, and is another element that adds to the stock's long-term attractiveness.

Recommended For You

About NVS Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
NVS--
Novartis AG